Company News 12 Dec 2024 Orthocell Achieves Major Milestone with First Sales of Remplirâ„¢ in Singapore Orthocell has today announced the achievement of first sales of Remplirâ„¢ in Singapore, marking another significant milestone in its global… Orthocell
Company News 02 Dec 2024 Orthocell successfully completes US FDA 510(k) regulatory study for Remplirâ„¢ Orthocell has today reached another significant milestone with the successful completion of its Remplirâ„¢ 510(k) nerve repair regulatory study, validating… Orthocell
Company News 27 Nov 2024 Orthocell Appoints Exclusive Distributor to Commence Sales of Remplirâ„¢ in Singapore Orthocell has announced that it has appointed Device Technologies Asia as the exclusive distributor of market leading peripheral nerve repair… Orthocell
Company News 11 Nov 2024 Appointment of Key US Executives to Lead Remplirâ„¢ Launch Orthocell has appointed two experienced US-based executives to drive the market launch and sales of Remplirâ„¢ following the expected US… Orthocell
Company News 25 Oct 2024 $17 million placement to fund US launch of Remplirâ„¢ and drive further growth Orthocell has today announced that it has received firm commitments for a $17 million capital raising via an institutional placement. Orthocell
Company News 08 Oct 2024 Orthocell Receives Regulatory Approval for Remplirâ„¢ in Singapore Orthocell has received regulatory approval from the Health Sciences Authority (HSA) in Singapore, allowing the Company to commence sales of… Orthocell
Company News 07 Oct 2024 Orthocell Reports Second Consecutive Quarter of Record Revenue Orthocell has today announced continued growth in sales of its market-leading medical devices, Striate+â„¢ and Remplirâ„¢. Orthocell
Company News 06 Sep 2024 First Sales of Striate+â„¢ in New and Significant Market of Canada Orthocell has today announced global distribution partner BioHorizons has recorded a fast transition to first sales of Striate+â„¢ in the… Orthocell
Company News 05 Sep 2024 Petra Capital Research Report | September 2024 Petra Capital has released a research report valuing #Orthocell (ASX:OCC) at A$1.28 per share. The report summarises Orthocell’s revenue growth, and… Orthocell
Company News 29 Jul 2024 Orthocell submits Singapore Regulatory Application for Striate+â„¢ Orthocell has announced its application to market and sell its leading guided bone and tissue repair product Striate+â„¢ in Singapore,… Orthocell
